PMID- 22064554
OWN - NLM
STAT- MEDLINE
DCOM- 20120702
LR  - 20141120
IS  - 1539-2031 (Electronic)
IS  - 0192-0790 (Linking)
VI  - 46
IP  - 4
DP  - 2012 Apr
TI  - HER-2/neu overexpression is an independent prognostic factor for intestinal-type 
      and early-stage gastric cancer patients.
PG  - e31-7
LID - 10.1097/MCG.0b013e31823457ea [doi]
AB  - GOALS: To evaluate the HER-2/neu protein level by immunohistochemistry (IHC) and 
      its gene amplification by fluorescence in situ hybridization (FISH) in gastric 
      cancer samples, and the relevance to the prognosis of gastric cancer patients. 
      STUDY: HER-2/neu overexpression and gene amplification were examined with 
      semiquantitative standardized IHC in 775 formalin-fixed paraffin-embedded gastric 
      cancer samples, and 252 of these cases were analyzed with FISH. RESULTS: Of the 
      775 gastric cancer samples examined by IHC, a total of 88 (11%) cases were 
      positive for HER-2/neu overexpression at a score of 3+; another 44 (6%) cases 
      were equivocal with a score of 2+; and the rest 643 (83%) cases were negative 
      scored as 0/1+. Intestinal-type and early-stage cancers exhibited higher rate of 
      HER-2/neu overexpression than those of diffuse/mixed-type and advanced cancers 
      (P<0.05). Intestinal-type and early-stage cancers with HER-2/neu overexpression 
      also exhibited short 5 year survival rates (21% vs. 47%, P=0.027; 29% vs. 60%, 
      P=0.037) than HER-2/neu-negative cases, but not in the diffuse/mixed-type and 
      advanced stage cancers. By FISH analysis, it was shown that 70% (60/86) of IHC 3+ 
      had HER-2/neu gene amplication. In contrast, only 14% (6/43) of IHC 2+ cases, and 
      2.5% (3) of the 120 cases with IHC 0/1+ randomly selected showed HER-2/neu gene 
      amplification. CONCLUSIONS: HER-2/neu overexpression may be used as an 
      independent prognostic factor for intestinal-type and early-stage gastric cancer 
      patients. IHC 3+ and 2+ cases should be further detected by FISH to assess 
      HER-2/neu gene status. Patients with HER-2/neu amplification also might 
      constitute potential candidates for targeted therapy with trastuzumab.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Pathology, Dongfang Hospital, Fuzhou, Fujian, China.
FAU - Zhong, Shan
AU  - Zhong S
FAU - Chen, Juan
AU  - Chen J
FAU - Yu, Yinghao
AU  - Yu Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Gastroenterol
JT  - Journal of clinical gastroenterology
JID - 7910017
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Follow-Up Studies
MH  - Gene Amplification
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Prospective Studies
MH  - Receptor, ErbB-2/*genetics
MH  - Stomach Neoplasms/*genetics/pathology
MH  - Survival Rate
EDAT- 2011/11/09 06:00
MHDA- 2012/07/03 06:00
CRDT- 2011/11/09 06:00
PHST- 2011/11/09 06:00 [entrez]
PHST- 2011/11/09 06:00 [pubmed]
PHST- 2012/07/03 06:00 [medline]
AID - 10.1097/MCG.0b013e31823457ea [doi]
PST - ppublish
SO  - J Clin Gastroenterol. 2012 Apr;46(4):e31-7. doi: 10.1097/MCG.0b013e31823457ea.